Alto Neuroscience (ANRO) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alto Neuroscience (ANRO) has outperformed MoonLake Immunotherapeutics (MLTX) over the past year, gaining 91.5% versus a loss of 12.6%. Alto Neuroscience is the larger company by market cap ($1.02 billion vs $942.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANRO | MLTX |
|---|---|---|
| Share price | $25.37 | $11.07 |
| Market cap | $1.02B | $942.13M |
| 1-day change | -4.30% | +0.36% |
| YTD return | +42.53% | -16.01% |
| 1-year return | +91.47% | -12.63% |
| 5-year return | — | +12.16% |
| EPS (TTM) | $-2.32 | $-3.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-63.24M | $-227.32M |
| 52-week high | $37.48 | $23.29 |
| 52-week low | $12.51 | $9.46 |
| Distance from 52-week high | -32.31% | -52.47% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +52.42% | +173.62% |
| Average volume | 614.92K | 1.64M |
| Shares outstanding | 40.11M | 85.11M |
| Employees | 68 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANRO has outperformed MLTX by 104.1 percentage points over the past year.
About Alto Neuroscience
ANRO stock →Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 68 employees
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
ANRO vs MLTX FAQ
Which is bigger, Alto Neuroscience or MoonLake Immunotherapeutics?
Alto Neuroscience (ANRO) is larger, with a market capitalization of $1.02B compared with $942.13M for MoonLake Immunotherapeutics (MLTX).
Which stock has performed better over the past year, ANRO or MLTX?
ANRO returned +91.47% over the past 12 months, compared with -12.63% for MLTX (price return, excluding dividends). Past performance does not predict future results.
Are Alto Neuroscience and MoonLake Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.